Results 231 to 240 of about 78,685 (264)
Some of the next articles are maybe not open access.
Chasing Cancer with Chimeric Antigen Receptor Therapy
Immunotherapy, 2012Many attempts to use genetically modified T cells to halt tumor progression have been met with disappointment and significant challenges in the successful application within human patients. Porter et al., however, describe the use of genetically modified lymphocytes bearing a chimeric antigen receptor that bypasses many of the common limitations of ...
Christina D, Pham, Duane A, Mitchell
openaire +2 more sources
A closer look at chimeric antigen receptor specificity
Cytotherapy, 2014The success of chimeric antigen receptor (CAR)expressing T cells as therapy for refractory hematologic malignancies (1) has spurred ongoing efforts to extend their application toward other difficult-totreat tumors. High-grade gliomas, for example, are prime candidates.
openaire +2 more sources
Chimeric antigen receptor therapy in hematologic malignancies
JAAPAABSTRACT Chimeric antigen receptor (CAR) T-cell therapy has led to significant advances in the treatment of blood cancers such as leukemia, lymphoma, and multiple myeloma, and now shows promise for solid tumors. This type of immunotherapy can achieve high response rates in patients with hematologic malignancies, but carries serious adverse ...
Elizabeth, Brownlee +2 more
openaire +2 more sources
Technologies for chimeric antigen receptor transgene delivery
Trends in Molecular MedicineEx vivo chimeric antigen receptor (CAR) T cell therapy has achieved clinical success in hematological malignancies; yet, viral transduction risks insertional mutagenesis. Developing safe and efficient nonviral approaches for the genetic engineering of T cells and other immune cells is the key to next-generation immunotherapy for cancer and noncancerous
Yudian Xiao +6 more
openaire +2 more sources
Chimeric antigen receptor Treg therapy in transplantation
Trends in ImmunologyIn the quest for more precise and effective organ transplantation therapies, chimeric antigen receptor (CAR) regulatory T cell (Treg) therapies represent a potential cutting-edge advance. This review comprehensively analyses CAR Tregs and how they may address important drawbacks of polyclonal Tregs and conventional immunosuppressants.
Siawosh K, Eskandari +2 more
openaire +2 more sources
Asian Medical Journal and Alternative Medicine, 2018
Manop Pitukpakorn, Somchai Bovornkitti
openaire +1 more source
Manop Pitukpakorn, Somchai Bovornkitti
openaire +1 more source
Critical care management of chimeric antigen receptor T‐cell therapy recipients
Ca-A Cancer Journal for Clinicians, 2022Alexander Shimabukuro-Vornhagen +2 more
exaly